Jackson Laboratory

The Ren Lab

Principal Investigator: Guangwen "Gary" Ren, Ph.D.

The Jackson Laboratory
Bar Harbor, ME

Connect with me:

To study tumor microenvironment and tumor immunology in cancer therapeutic resistance and metastatic relapse

OUR RESEARCH FOCUS

The Ren group mainly focuses on elucidating how mesenchymal lineage cells (mesenchymal stem cells and fibroblasts) and immune-regulatory myeloid cells (neutrophils and macrophages) modulate the adaptive immune responses in cancer treatment resistance and metastatic relapse. These studies will fully take advantage of the unique research platform--patient-derived xenograft (PDX) tumors in humanized mouse models at The Jackson Laboratory, with the research goal to develop novel strategies targeting tumor microenvironment to improve the efficacies of conventional cancer therapies and new therapeutics such as immunotherapy.

Full Scientific Report

The Jackson Laboratory Cancer Center

View all research positions

Open Positions

Job	Job Title	Location	Description

Lab Staff

Li Hua, Ph.D.

Alumni

Stromal cells may provide a positive or negative role in modulating the immunotherapy.
Guangwen "Gary" Ren, Ph.D.

Assistant Professor

To study tumor microenvironment and tumor immunology in cancer therapeutic resistance and metastatic relapse.

Selected Publications

View full list of publications

Blog PostJanuary 20, 2021
Advancing Humanized NSGTM Mice for Immuno-Oncology Testing
Immunologically humanized NSGTM and its variant strains are a powerful system that facilitates cutting-edge in vivo preclinical testing of a wide range of immuno-oncology therapeutic candidates.
Research HighlightJanuary 12, 2021
Few mutations, important difference in cancer cells
JAX Professor Sheng Li, Ph.D., presents a tool, epihet, that automates the epigenetic analysis of AML cells. epihet allows researchers to assess epigenetic differences between cells, identify genomic locations where the differences occur, and associate cellular epigenetic profiles with cancer-related biological function.
Research HighlightDecember 12, 2020
JAX pioneers way to analyze cancer image data
A team led by JAX Associate Professor Jeffrey Chuang, Ph.D., has developed image processing and convolutional neural network software that can combine images of cancers from different organs to reveal how they are related to one another.
Press ReleaseDecember 02, 2020
JAX to expand advanced cancer clinical trial
JAX’s Maine Cancer Genomics Initiative joins nationwide TAPUR Study, providing access to targeted cancer therapies for rural population.

Research HighlightJanuary 18, 2021
JAX uses genetic models to fight CUP
A JAX team developed CUP-AI-Dx, a machine learning tool that uses RNA sequence data for analysis. The researchers show that CUP-AI-Dx provides an important clinical tool to help guide therapies for CUP patients.
Research HighlightJanuary 07, 2021
JAX scientist analyzes PDX models
PDX models provide researchers with the ability to work with tumors directly from patients within a living (in vivo) system, making them a preeminent platform for preclinical cancer research.
- Cancer/Tumors
- Cancer
Press ReleaseDecember 07, 2020
JAX's multi-pronged approach to triple-negative breast cancers
National Cancer Institute grant to JAX funds multi-pronged approach to address triple-negative breast cancers.
- Breast Cancer
- Cancer
Press ReleaseDecember 02, 2020
A Rich Philanthropic History, an Innovative Spirit
JAX supporter Diana Davis Spencer says her entrepreunerial spirit and passion for philanthropy are what motivate her to give.
- Vision
- Aging

The Ren Lab

Principal Investigator: Guangwen "Gary" Ren, Ph.D.

Thank you. Your message has been sent.

Contact The Ren Lab

OUR RESEARCH FOCUS

Open Positions

Selected Publications

Advancing Humanized NSGTM Mice for Immuno-Oncology Testing

Few mutations, important difference in cancer cells

JAX pioneers way to analyze cancer image data

JAX to expand advanced cancer clinical trial

JAX uses genetic models to fight CUP

JAX scientist analyzes PDX models

JAX's multi-pronged approach to triple-negative breast cancers

A Rich Philanthropic History, an Innovative Spirit